-
Development of Hsf1 Effectors as Parkinson's Disease Therapeutics
… target for the treatment of Parkinson’s disease. … Dyskinesia … Clinical Trial … Texas … United States … MJFF …
-
Validation of Lysosomal Enzymes Assay in CSF - One-year Extension of the RRIA: CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
… achieve a timely and focused pharmacological treatment. … Dyskinesia … Clinical Trial … California … United States … …
-
Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway
… hampered by serious side effects, including L-DOPA -induced dyskinesias (LID), compulsive behaviors and somnolence. … clinical development. May 2014 … Symptoms & Side Effects … Dyskinesia … Therapeutic Development … Neuropharmacology … …
-
Validation of Enzymatic Activity and Neuropathology in G2019S LRRK2-induced Dopaminergic Neurodegeneration in a Pre-clinical Model of Parkinson's Disease
… essential tools needed to develop this model of PD.’ … Dyskinesia … Clinical Trial … New York … United States … …
-
The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex
… and its associated cognitive phenotype in PD patients. … Dyskinesia … Clinical Trial … North Carolina … United States …
-
Multicenter Clinical Trial of Deep Brain Stimulation in Early Stage Parkinson’s Disease
… launch this large-scale multicenter study. … Epidemiology … Dyskinesia … Clinical Trial … Deep Brain Stimulation … …